At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
LNA043 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-part, Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 Injections in Regenerating the Articular Cartilage of the Knee in Patients With Articular Cartilage Lesions (Part A) and in Patients With Knee Osteoarthritis (Part B).
In Brief
A Phase 2 clinical trial evaluating LNA043 and Placebo for Osteoarthritis. Completed, enrolled 142 participants across 19 sites in 3 countries.
Detailed Summary
The purpose of this two-part study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043, in regenerating the articular surface in patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesCzechia, Denmark, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartSep 2017
Primary CompletionSep 2022
TodayJul 2026
First PostedSep 7, 2017
Enrollment StartSep 12, 2017
Primary CompletionSep 6, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.8 years ago
Interventions
LNA043biological
LNA043 intra-articular injection
Placeboother
Placebo intra-articular injection